Carol L. Karp, M.D.
Carol L. Karp, M.D. (Residency, 1993) is the Richard K. Forster Chair in Ophthalmology and the Dr. Ronald and Alicia Lepke Endowed Professor in Corneal Diseases at the University of Miami Health System Bascom Palmer Eye Institute in Miami, Florida. A trailblazing clinician and researcher, her work in both non-surgical therapeutics and ocular imaging have transformed the diagnosis and management of ocular surface tumors.
Years before eye injections became standard practice, she pioneered the injection of interferon around the eye along with topical drops, with remarkable curative outcomes. Dr. Karp also helped develop a non-invasive “optical biopsy” known as OCT, which yields more precise diagnostics and treatment planning for benign and malignant ocular tumors.
Since winning the LaBerge and Slocum resident awards at Kellogg for her first publication in Ophthalmology as a resident, she now has over 130 peer-reviewed manuscripts, and more than 25 chapters. She has also received multiple awards from the AAO and AMA for her service and mentorship.
“I’m forever grateful for my time at Kellogg,” she says. “I discovered my love of research there, and by example, my Kellogg mentors showed me how to be an ethical, thorough investigator and a compassionate, patient-focused clinician.”
Ryan Fante, M.D.
Ryan Fante, M.D. (Residency, 2014) is a practicing ophthalmologist at the Sansum Clinic in Santa Barbara, California.
Celebrating its 98th anniversary in 2019, the Sansum Clinic is the oldest and largest not-for-profit outpatient healthcare provider on California’s central coast. Dr. Fante is one of six ophthalmologists in a multispecialty group of 180 physicians.
Dr. Fante’s practice includes cataract and minimally invasive glaucoma surgery as well as injections and laser treatments for macular degeneration and diabetic retinopathy. Since joining the clinic in 2014, he has also stepped into leadership roles on Sansum’s Clinician Advisory Committee and Peer Review and Credentialing Committee.
“Unlike many of my peers, I did not elect to do a fellowship,” he says. “But thanks to my residency at Kellogg, I was more than prepared to hit the ground running in a busy, comprehensive ophthalmology practice.”
Raymond Cho, M.D.
Raymond Cho, M.D. (Fellowship, 2009) is director of ophthalmic plastic and reconstructive surgery at the Ohio State University Wexner Medical Center.
Dr. Cho specializes in plastic and reconstructive surgery of the eyelids, orbit and lacrimal drainage system. He is also an associate professor at the Ohio State University College of Medicine and a member of the OSU Wexner Medical Center skull base team. He is well known for his expertise in the treatment of thyroid orbitopathy, orbital trauma and complex periocular and orbitofacial reconstruction after cancer resection.
“I was fortunate to have completed my fellowship at Kellogg,” he says. “Kellogg provided world-class training in ophthalmic plastic and reconstructive surgery, preparing me for the wide variety of surgical challenges I face in my clinical practice.”
Courtney Kauh, M.D.
Courtney Kauh, M.D. (Residency, 2015) is a practicing oculoplastic surgeon at the Ohio State University Wexner Medical Center.
Dr. Kauh joined the Wexner Medical Center’s Havener Eye Institute in 2017. Her busy practice includes surgical procedures to treat orbital and periorbital tumors, eye trauma and diseases, and eyelid and tear duct abnormalities. She also coordinates a comprehensive orbital dissection course for ophthalmology residents, and cares for patients at the Veteran’s Administration facility in Columbus.
“My residency experience at Kellogg was exceptional,” says Dr. Kauh. “I had terrific instructors in every discipline, many of whom remain colleagues and mentors to this day.”
The surgical training Dr. Kauh received played a big role in her choice to specialize
Anthony Adamis, M.D.
Anthony Adamis, M.D. (Residency, 1989) has been elected to the National Academy of Medicine. Considered one of the highest honors in the fields of health and medicine, election to the Academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Dr. Adamis is best known for co-discovering the key role of vascular endothelial growth factor (VEGF) in eye disease, and obtaining FDA approval for the first anti-VEGF drug in ophthalmology, which treats millions of people annually. Today, he is senior vice president of development innovation at Genentech, a biotechnology firm, member of the Roche Group, and a lecturer in ophthalmology at Harvard University Medical School.
“At Michigan, I was trained to ask how things work, so I decided to try my hand at research,” Dr. Adamis told a Kellogg grand rounds audience in 2017, upon receiving the Michigan Medicine Alumni Society’s Distinguished Achievement Award. He credits U-M and Kellogg with providing “the kind of guidance and support that a very junior scientist can only wish for.”